Documentos relacionados

1. MYELODYSPLASTIC SYNDROME: DIAGNOSIS, TREATMENT AND PROGNOSIS (LITERATURE REVIEW).
2. Successful treatment of a B/T MPAL patient by chemo-free treatment with venetoclax, azacitidine, and blinatumomab.
3. Adverse Event Profile of Azacitidine: Analysis by Route of Administration Using Japanese Pharmacovigilance Database.
4. Five-day versus 7-day treatment regimen with azacitidine in lower risk myelodysplastic syndrome: A phase 2, multicenter, randomized trial.
5. FUS-ERG induces late-onset azacitidine resistance in acute myeloid leukaemia cells.
6. Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice.
7. VEXAS: where do we stand 2 years later?
8. Real-world practice-based prognostic model for higher-risk myelodysplastic syndromes treated with azacitidine monotherapy: The Kyoto prognostic scoring system.
9. Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms.
10. Insights into the Inhibitory Mechanisms of the Covalent Drugs for DNMT3A.